Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 7, 2012, Pages 1208-1215

  Videira, Mafalda ^a   Almeida, António J ^a   Fabra, ngels ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Lung metastases; Paclitaxel; Pulmonary administration; SLN PTX; Solid lipid nanoparticles

Indexed keywords

ANTICANCER DRUG; ANTITUMOR EFFECT; CANCER THERAPY; COLLOIDAL CARRIERS; COLLOIDAL SYSTEM; HIGH CONCENTRATION; LIPID NANOCARRIER; LUNG CANCER; LUNG METASTASIS; PACLITAXEL; POORLY SOLUBLE DRUGS; RESEARCH EFFORTS; SLN-PTX; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES; SOLID TUMORS; THERAPEUTIC INDEX;

CHEMOTHERAPY; DISEASES; ENZYME INHIBITION; NANOPARTICLES; TOXICITY; TUMORS;

BIOLOGICAL ORGANS;

NANOCARRIER; PACLITAXEL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LUNG; LUNG NEOPLASMS; NEBULIZERS AND VAPORIZERS; PACLITAXEL; RATS;

MURINAE;

EID: 84866515787     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.12.007     Document Type: Article

References (51)

1. Azarmi S., Roa W., Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008, 60:863-875.
2. Cuenca A.G., Jiang H., Hochwald S.N., Delano M., Cance W.G., Grobmyer S.R. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006, 107:459-466.
3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
4. Zhang L., Gu F., Chan J., Wang A., Langer R., Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clini Pharmacol Ther 2008, 83:761-769.
5. Andrade F., Videira M., Ferreira D., Sarmento B. Nanocarriers for pulmonary administration of peptides an therapeutic proteins. Nanomedicine 2011, 6:123-141.
6. Sharma S., White D., Imondi A.R., Placke M.E., Vail D.M., Kris M.G. Development of inhalational agents for oncologic use. J Clin Oncol 2001, 19:1839-1847.
7. Ally J., Martin B., Behradkhamesee M., Roa W., Amirfazli A. Magnetic targeting of aerosol particles for cancer therapy. J Mag Magn Mat 2005, 293:442-449.
8. Rao R.D., Markovic S.N., Anderson P.M. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003, 3:239-250.
9. Gautam A., Koshkina N. Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 2003, 3:287-296.
10. Koshkina N., Waldrep J.C., Roberts L.E., Golunski E., Melton S., Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001, 7:3258-3262.
11. Crown J., O'Leary M., Ooi W.S. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004, 9:24-32.
12. Ettinger D.S. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin Radiat Oncol 1999, 2:48-50.
13. Murphy W.K., Fossella F.V., Winn R.J., Shin D.M., Hynes H.E., Gross H.M., et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993, 85:384-388.
14. Giannakakou P., Robey R., Fojo T., Blagosklonny M.V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001, 20:3806-3813.
15. Huisman C., Ferreira C.G., Broker L.E., Rodriguez J.A., Smit E.F., Postmus P.E., et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002, 8:596-606.
16. Li R., Moudgil T., Ross H.J., Hu H.M. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005, 12:292-303.
17. Wang F., Cai Y., Zhao W., Liu H., Fu Z., Han R. Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of e-cadherin and nm23 expression. J Pharmacol Sci 2003, 93:197-203.
18. Zaffaroni N., Silvestrini R., Orlandi L., Bearzatto A., Gornati D., Villa R. Induction of apoptosis by Taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells. Br J Cancer 1998, 77:1378-1385.
19. Mader K. Solid Lipid nanoparticles as drug carriers. Nanoparticulates as drug carriers 2006, 187-212. Imperial College Press, Northeastern University, MA. V. Torchilin (Ed.).
20. Lee M.K., Lim S.J., Kim C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007, 28:2137-2146.
21. Shaji J., Jain V. Solid lipid nanoparticles: a novel carrier for chemotherapy. Int J Pharm Pharm Sci 2010, 2:8-17.
22. Videira M.A. Lipid nanoparticles as drug transporting systems for lung administration 2008, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
23. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002, 10:607-613.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immun Methods 1983, 65:55-63.
25. Llorens A., Vinyals A., Alía P., López-Barcons L., Gonzalez-Garrigues M., Fabra A. Metastatic ability of MXT mouse mammary subpopulations correlates with clonal expression and/or membrane-association of gelatinase A. Molecular Carcinogenesis 1997, 19:54-66.
26. Jones A.T., Gumbleton M., Duncan R. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv Drug Del Rev 2003, 55:1353-1357.
27. Harush-Frenkel O., Debotton N., Benita S., Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007, 353:26-32.
28. Vasir J.K., Labhasetwar V. Biodegradable Nanoparticles for cytosolic delivery of therapeutics. Adv Drug Del Rev 2007, 59:718-728.
29. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88.
30. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J of Pharm 2006, 320:150-156.
31. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000, 210:61-67.
32. Serpe L., Catalano M.G., Cavalli R., Ugazio E., Bosco O., Canaparo R., et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004, 58:673-680.
33. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., Neckers L.M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996, 56:1851-1854.
34. Burkhart C.A., Berman J.W., Swindell C., Horwitz S.B. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-a gene expression and cytotoxicity. Cancer Res 1994, 54:5779-5782.
35. Ruenraroengsak P., Cook J.M., Florence A.T. Nanosystem drug targeting: Facing up to complex realities. J Control Release 2010, 141:265-276.
36. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006, 23:1417-1450.
37. Kim K.Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 2007, 3:103-110.
38. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Del Rev 2004, 56:1649-1659.
39. Maeda H., Wua J., Sawaa T., Matsumurab Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
40. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11:812-818.
41. Witte M.H., Jones K., Wilting J., Dictor M., Selg M., McHale N., et al. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev 2006, 25:159-184.
42. Fang F., Sawa T., Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49.
43. Torchilin V.P. Nanoparticulates as drug carriers 2006, Imperial College Press.
44. Furgeson D.Y., Yockman J.W., Janat M.M., Kim S.W. Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes. Mol Ther 2004, 9:837-845.
45. Harivardhan R.L., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.S.R. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 2005, 105:185-198.
46. Xu Z., Gu W., Huang J., Sui H., Zhou Z., Yang Y., et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005, 288:361-368.
47. Koshkina N.V., Golunski E., Roberts E., Gilbert B., Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004, 115:395-404.
48. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004, 269:37-49.
49. Torchilin V.P. Recent approaches to intracellular delivery of drugs and dna and organelle targeting. Annu Rev Biomed Eng 2006, 8:343-375.
50. Hodoshima N., Udagawa C., Ando T., Fukuyasu H., Watanabe H., Nakabayashi S. Lipid nanoparticles for delivering antitumor drugs. Int J Pharm 1997, 146:81-92.
51. Vonarbourg A., Passirani C., Saulnier P., Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373.